BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

類似資料

• Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
  著者:: Nyman, H, 等
  出版事項: (2009)
• Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
  著者:: Nyman, H, 等
  出版事項: (2009)
• The significance of FOXP1 in diffuse large B-cell lymphoma
  著者:: Gascoyne, D, 等
  出版事項: (2016)
• An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
  著者:: Marta Rodríguez, 等
  出版事項: (2022-08-01)
• MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
  著者:: Borovecki, A, 等
  出版事項: (2007)